Cargando…

Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis

Objective. To evaluate radiographic and clinical outcomes up to 24 months in patients with RA enrolled in the Canadian Methotrexate and Etanercept Outcome study. Methods. In this open-label non-inferiority trial, patients with inadequate response to MTX received etanercept plus MTX for 6 months and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keystone, Edward C., Pope, Janet E., Thorne, J. Carter, Poulin-Costello, Melanie, Phan-Chronis, Krystene, Vieira, Andrew, Haraoui, Boulos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710802/ https://www.ncbi.nlm.nih.gov/pubmed/26361879 http://dx.doi.org/10.1093/rheumatology/kev338

Ejemplares similares

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH)
por: Lee, Jason J., et al.
Publicado: (2016)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH)
por: Barnabe, Cheryl, et al.
Publicado: (2015)

Effects of Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis: Results From the SEAM-RA Trial
por: Curtis, Jeffrey R., et al.
Publicado: (2023)

Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study
por: Haraoui, Boulos, et al.
Publicado: (2011)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)
por: Cohen, Stanley B, et al.
Publicado: (2021)

Joint Estimation of Remission and Response for Methotrexate‐Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta‐Analysis
por: Pokharel, Gyanendra, et al.
Publicado: (2019)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
por: Pope, Janet E., et al.
Publicado: (2019)

Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial
por: Pope, Janet, et al.
Publicado: (2012)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Casual effect of methotrexate+etanercept/infliximab on survival of patients with rheumatoid arthritis
por: Akhlaghi, Saeed, et al.
Publicado: (2019)

The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
por: Chen, Fangfang, et al.
Publicado: (2023)

Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
por: Fleischmann, Roy, et al.
Publicado: (2022)

Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study
por: Haraoui, Boulos, et al.
Publicado: (2022)

Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
por: Chen, Fangfang, et al.
Publicado: (2023)

A Bridge Too Far? Real‐World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort
por: Andersen, Kathleen M., et al.
Publicado: (2021)

Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
por: Bessette, Louis, et al.
Publicado: (2023)

Predictors of Influenza Vaccination in Early Rheumatoid Arthritis 2017‐2021: Results From the Canadian Early Arthritis Cohort
por: Ta, Viviane, et al.
Publicado: (2022)

Oral non-Hodgkin’s lymphoma in a patient with rheumatoid arthritis treated with etanercept and methotrexate
por: Georgakopoulou, Eleni A., et al.
Publicado: (2015)

High Adherence to System‐Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years
por: Barber, Claire E. H., et al.
Publicado: (2018)

Changes in Plasma IL-6, Plasma VEGF and Serum YKL-40 During Treatment with Etanercept and Methotrexate or Etanercept Alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
por: Knudsen, Lene Surland, et al.
Publicado: (2009)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE
por: Papp, K.A., et al.
Publicado: (2015)

Etanercept/methotrexate: COVID-19: case report
Publicado: (2020)

Etanercept/methotrexate: Treatment failure: case report
Publicado: (2021)

The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry
por: Becciolini, Andrea, et al.
Publicado: (2016)

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
por: Bessette, Louis, et al.
Publicado: (2017)

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set
por: Bykerk, Vivian P, et al.
Publicado: (2016)

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
por: Smolen, Josef S., et al.
Publicado: (2018)

ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)
por: Pope, Janet E, et al.
Publicado: (2018)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
por: Chen, Hsin-Hua, et al.
Publicado: (2016)

A Patient with Rheumatoid Arthritis under Methotrexate and Etanercept Treatment Presenting with Fever and Pancytopenia: An Unexpected Guest
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis
por: Khraishi, Majed, et al.
Publicado: (2019)

Effects of methotrexate and etanercept treatment in moderate and severe psoriasis
por: Benites, Elizabeth, et al.
Publicado: (2022)

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
por: Smolen, Josef S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g583k1fssn93560o7tlf2sprc5